Dmitry Nosov

机构：Central Clinical Hospital and Polyclinic, Presidential Executive Office, Central Clinical Hospital · ORCID：0000-0001-8415-5197

发表论文 105 篇 · 总被引 6823 次 · h-index 19

代表论文

• Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020 · The Lancet Oncology · 被引 764)
• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 698)
• Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma (2024 · New England Journal of Medicine · 被引 181)
• Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study (2023 · European Urology · 被引 147)
• Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. (2021 · Journal of Clinical Oncology · 被引 109)
• Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. (2023 · Journal of Clinical Oncology · 被引 80)